TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00000620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hyperglycemic Agents
Description: Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hyperglycemic Agents
Description: Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive Agents
Description: Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive Agents
Description: Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded fenofibrate or placebo plus simvastatin
Description: Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blinded fenofibrate or placebo plus simvastatin
Description: Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
Study: NCT05382585

Intervention type: OTHER
Intervention: Next generation Sequencing
Description: Next generation sequencing for 161 genes
Study: NCT03009773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation multitasking walking.
Description: rehabilitation multitasking walking.
Study: NCT02899026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sirukumab
Description: Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match sirukumab
Description: Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
Study: NCT03009773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional walking rehabilitation
Description: Traditional walking rehabilitation
Study: NCT01876446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Irinotecan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02899026

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone /Prednisone placebo
Description: Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone /Prednisone placebo
Description: Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone /Prednisone placebo
Description: Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
Study: NCT03599284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicagrel 5mg
Description: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicagrel 6mg
Description: Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
Study: NCT00961844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT03599284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicagrel 7.5mg
Description: Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
Study: NCT00791466

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo supplementation from enrolment \<14 wk of gestation until delivery
Study: NCT03599284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
Study: NCT04168359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: absorbable semi-barbed suture
Description: Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
Study: NCT01320384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: O2 conventional
Description: standard low flow therapy
Study: NCT01595269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eHealth education
Description: In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
Study: NCT02246699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KiOnutrime®-Cs
Description: The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
Study: NCT02095678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver biopsy
Description: patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: free-breathing MRI
Description: All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: free-breathing MRI
Description: All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality
Study: NCT01320384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2-HFN : high flow nasal oxygen therapy
Description: The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation
Description: The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
Study: NCT01772797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 is a capsule to be taken daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
Study: NCT02432157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTS 3%
Description: 3% HTS at a dose of 250 ml every 6 hours for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluid management
Description: Routine fluid management strategy as pre-specified by our SAH management protocol.
Study: NCT00230178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase (SR29142)
Description: 30-min IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase (SR29142)
Description: 30-min IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Oral administration
Study: NCT00693043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride
Description: Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
Study: NCT01208987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication History was printed
Study: NCT00925639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflavone
Description: 150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch pill
Study: NCT05243446

Intervention type: DRUG
Intervention: Losartan
Description: losartan treatment
Study: NCT05204498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education plan and adherence to exercise
Description: Through phone calls with a motivating sense at any time of the day, twice a week.~* It will be recorded in an Excel table each time the patient is called.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again.
Study: NCT00791466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine
Description: Daily supplementation with 200 µg iodine from enrolment \<14 wk of gestation until delivery
Study: NCT02956486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenbecestat
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenbecestat
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study: NCT00749372

Intervention type: OTHER
Group type: OTHER
Intervention: T2* Cardiac and Liver MRI
Description: Patients will undergo an MRI of the heart and liver.
Study: NCT01859754

Intervention type: BIOLOGICAL
Intervention: Octagam 5%
Description: Intravenous immunoglobulin 5%

Intervention type: BIOLOGICAL
Intervention: Other marketed IVIG product
Description: Any intravenous immunoglobulin marketed product approved for the treatment of PID
Study: NCT00103181

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal accelerated partial breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Description: Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MammoSite or other single-entry intracavitary device
Study: NCT03516071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg, QD
Description: Brivanib Alaninate 800 mg QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib 400 mg, BID
Description: Brivanib Alaninate 400 mg BID, PO
Study: NCT03333824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP1A2 (caffeine)
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C19 (omeprazole)
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP3A (midazolam)
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kytril (granisetron)
Description: Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wee-1 kinase inhibitor AZD1775
Description: Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study: NCT01113411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHILOS™ locked plate system by Synthes Canada©
Description: The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHILOS™ locked plate system by Synthes Canada©
Description: The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early and intensive exercise program
Description: A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation program
Description: The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
Study: NCT02517502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: 4 capsules of 400 mg DHA daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched, blinded placebo
Study: NCT00845299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost punctal plug
Description: Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost punctal plug
Description: Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artificial tears preserved with Benzalkonium Chloride
Study: NCT03315702

Intervention type: OTHER
Intervention: mechanical ventilation
Description: mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
Study: NCT00599144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaparocholecystectomy
Description: Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaparocholecystectomy
Description: Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videolaparocholecystectomy
Description: Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: videolaparocholecystectomy
Description: Group3: control group without any local anesthetic use.
Study: NCT03106857

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group A
Description: Group A Physical activity and low caloric diet for
Study: NCT04835740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity Interval Training
Description: All the participants underwent 5 weeks of High intensity interval training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity Interval Training
Description: All the participants underwent 5 weeks of High intensity interval training.
Study: NCT04916106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electroacupuncture
Description: give diffrent parameter TEA treatment for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electroacupuncture
Description: give diffrent parameter TEA treatment for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electroacupuncture
Description: give diffrent parameter TEA treatment for 4 weeks.
Study: NCT01797302

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Tablet form

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Tablet form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Tablet form
Study: NCT00748176

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: spinal anesthesia with bupivacaine
Study: NCT02129192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg capsule
Description: Amlodipine 5mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T80/H12.5 mg FDC tablet
Description: Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5 mg FDC tablet
Description: Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
Study: NCT00560872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remote magnetic catheter navigation
Description: use of the Stereotaxis system

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cavotricuspid isthmus ablation
Description: conventional (manual) approach
Study: NCT00836199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX vaccine
Description: NicVAX vaccine given 6 times over 6 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Placebo vaccine given 6 times over 6 months
Study: NCT02853318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04229186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EVOO-C
Description: Each patient will consume 10 mg total daily amount EVOO-C

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ROO
Description: Each patient will consume 10 mg total daily amount ROO